Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 20 | 2023 | 772 | 3.920 |
Why?
|
| Sexually Transmitted Diseases | 7 | 2023 | 91 | 3.810 |
Why?
|
| Sexual and Gender Minorities | 12 | 2024 | 192 | 3.450 |
Why?
|
| Pre-Exposure Prophylaxis | 11 | 2023 | 137 | 2.010 |
Why?
|
| Syphilis | 4 | 2023 | 27 | 1.860 |
Why?
|
| Smallpox Vaccine | 2 | 2023 | 12 | 1.810 |
Why?
|
| Vaccinia virus | 2 | 2023 | 19 | 1.140 |
Why?
|
| Viral Vaccines | 2 | 2023 | 43 | 1.100 |
Why?
|
| Homosexuality, Male | 13 | 2023 | 298 | 0.960 |
Why?
|
| Mental Health Services | 1 | 2023 | 48 | 0.920 |
Why?
|
| Sexual Health | 1 | 2023 | 14 | 0.890 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 66 | 0.870 |
Why?
|
| Vaccines | 1 | 2023 | 80 | 0.850 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 140 | 0.840 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 456 | 0.770 |
Why?
|
| Antiviral Agents | 2 | 2023 | 510 | 0.710 |
Why?
|
| Respiratory System | 1 | 2020 | 116 | 0.710 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.640 |
Why?
|
| Community Health Centers | 1 | 2019 | 113 | 0.630 |
Why?
|
| Coinfection | 3 | 2023 | 58 | 0.600 |
Why?
|
| Sexual Behavior | 4 | 2024 | 302 | 0.570 |
Why?
|
| Anti-HIV Agents | 3 | 2023 | 149 | 0.560 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 0.550 |
Why?
|
| Monkeypox virus | 3 | 2023 | 6 | 0.510 |
Why?
|
| Humans | 34 | 2024 | 86601 | 0.480 |
Why?
|
| Vaccination | 3 | 2023 | 254 | 0.450 |
Why?
|
| Students, Medical | 3 | 2023 | 384 | 0.450 |
Why?
|
| Male | 19 | 2023 | 40956 | 0.380 |
Why?
|
| United States | 6 | 2023 | 6665 | 0.350 |
Why?
|
| Adult | 10 | 2023 | 25640 | 0.340 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.300 |
Why?
|
| Pandemics | 3 | 2021 | 740 | 0.280 |
Why?
|
| Adolescent | 4 | 2023 | 8979 | 0.270 |
Why?
|
| Middle Aged | 7 | 2023 | 25017 | 0.260 |
Why?
|
| Sexual Partners | 2 | 2022 | 93 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2023 | 8475 | 0.240 |
Why?
|
| Cell Phone | 1 | 2023 | 37 | 0.230 |
Why?
|
| Students, Pharmacy | 1 | 2023 | 1 | 0.230 |
Why?
|
| Outpatients | 1 | 2023 | 94 | 0.230 |
Why?
|
| Vaccinia | 1 | 2022 | 3 | 0.230 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 30 | 0.220 |
Why?
|
| Female | 13 | 2023 | 44507 | 0.220 |
Why?
|
| Crowdsourcing | 1 | 2022 | 12 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 78 | 0.220 |
Why?
|
| Mycoplasma genitalium | 1 | 2022 | 2 | 0.220 |
Why?
|
| Mobile Applications | 1 | 2023 | 63 | 0.220 |
Why?
|
| Mycoplasma Infections | 1 | 2022 | 8 | 0.220 |
Why?
|
| Gonorrhea | 1 | 2022 | 18 | 0.210 |
Why?
|
| HIV-1 | 1 | 2023 | 163 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 25 | 0.210 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 58 | 0.210 |
Why?
|
| Incidence | 3 | 2023 | 1576 | 0.210 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 484 | 0.210 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1621 | 0.200 |
Why?
|
| Prosthesis-Related Infections | 1 | 2021 | 58 | 0.190 |
Why?
|
| Young Adult | 3 | 2023 | 5974 | 0.190 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 87 | 0.190 |
Why?
|
| Risk Factors | 2 | 2023 | 5416 | 0.190 |
Why?
|
| Racism | 1 | 2022 | 81 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 275 | 0.180 |
Why?
|
| Device Removal | 1 | 2021 | 161 | 0.180 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 129 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 239 | 0.180 |
Why?
|
| Reagins | 1 | 2019 | 1 | 0.180 |
Why?
|
| Boston | 1 | 2019 | 33 | 0.180 |
Why?
|
| Telemedicine | 1 | 2022 | 169 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 426 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 879 | 0.160 |
Why?
|
| Prevalence | 1 | 2021 | 1239 | 0.150 |
Why?
|
| Recurrence | 1 | 2019 | 1139 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 746 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 1034 | 0.130 |
Why?
|
| HIV | 2 | 2023 | 46 | 0.110 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 154 | 0.110 |
Why?
|
| Bias | 2 | 2023 | 127 | 0.110 |
Why?
|
| Gender Identity | 2 | 2022 | 52 | 0.100 |
Why?
|
| China | 2 | 2022 | 228 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2023 | 66 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2023 | 839 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 864 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2023 | 2378 | 0.070 |
Why?
|
| District of Columbia | 1 | 2023 | 20 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2023 | 4210 | 0.060 |
Why?
|
| Pyridones | 1 | 2023 | 51 | 0.060 |
Why?
|
| Physical Examination | 1 | 2024 | 149 | 0.060 |
Why?
|
| Unsafe Sex | 1 | 2023 | 42 | 0.060 |
Why?
|
| Chlamydia trachomatis | 1 | 2022 | 14 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2022 | 16 | 0.050 |
Why?
|
| Condoms | 1 | 2022 | 36 | 0.050 |
Why?
|
| Viral Load | 1 | 2023 | 148 | 0.050 |
Why?
|
| Bisexuality | 1 | 2022 | 32 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 27 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 85 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 751 | 0.050 |
Why?
|
| Health Status | 1 | 2023 | 360 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 129 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 10 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2020 | 24 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2020 | 41 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 238 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 64 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 508 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 370 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1685 | 0.040 |
Why?
|
| Mass Screening | 1 | 2021 | 617 | 0.040 |
Why?
|
| Decision Making | 1 | 2021 | 642 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1379 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 848 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2501 | 0.030 |
Why?
|
| Child | 1 | 2020 | 6926 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7988 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 18402 | 0.020 |
Why?
|